Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Qiao, Yong Chao ^a,b   Shen, Jian ^a   He, Lan ^c   Hong, Xue Zhi ^a   Tian, Fang ^b   Pan, Yan Hong ^a   Liang, Ling ^a   Zhang, Xiao Xi ^a   Zhao, Hai Lu ^a,b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; CYTOKINE; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

CD25+ T LYMPHOCYTE; CD4 LYMPHOCYTE PERCENTAGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY CONTROL; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMATIC REVIEW; IMMUNOLOGY;

CYTOKINES; DIABETES MELLITUS, TYPE 2; HUMANS; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-6; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84991672330     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/3694957     Document Type: Review

References (139)

1. J.-D. Lin, T.-L. Hsia, C.-Z. Wu et al., "The first and second phase of insulin secretion in naive Chinese type 2 diabetes mellitus, " Metabolism: Clinical and Experimental, vol. 59, no. 6, pp. 780-786, 2010.
2. C. Zhang, C. Xiao, P. Wang et al., "The alteration of Th1/Th2/ Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy, " Human Immunology, vol. 75, no. 4, pp. 289-296, 2014.
3. M. Saxena, N. Srivastava, and M. Banerjee, "Association of IL-6, TNF-α and IL-10 gene polymorphisms with type 2 diabetes mellitus, " Molecular Biology Reports, vol. 40, no. 11, pp. 6271-6279, 2013.
4. J. C. Pickup, M. B. Mattock, G. D. Chusney, and D. Burt, "NIDDMas a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X, " Diabetologia, vol. 40, no. 11, pp. 1286-1292, 1997.
5. A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, "Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS), " Circulation, vol. 102, no. 1, pp. 42-47, 2000.
6. J. M. Fernández-Real and W. Ricart, "Insulin resistance and chronic cardiovascular inflammatory syndrome, " Endocrine Reviews, vol. 24, no. 3, pp. 278-301, 2003.
7. Y. Quan, A. Huang, M. Ye et al., "Efficacy of laparoscopic mini gastric bypass for obesity and type 2 diabetesmellitus: A systematic review and meta-analysis, " Gastroenterology Research and Practice, vol. 2015, Article ID 152852, 13 pages, 2015.
8. A. P. de Sá Borges, C. M. Guidoni, O. de Freitas, and L. R. L. Pereira, "Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service, " Arquivos Brasileiros de Endocrinologia & Metabologia, vol. 55, no. 9, pp. 686-691, 2011.
9. G. V. Z. Dedoussis, A. C. Kaliora, and D. B. Panagiotakos, "Genes, diet and type 2 diabetes mellitus: A review, " Review of Diabetic Studies, vol. 4, no. 1, pp. 13-24, 2007.
10. R. A. Mathias, M. Deepa, R. Deepa, A. F. Wilson, and V. Mohan, "Heritability of quantitative traits associatedwith type 2 diabetes mellitus in large multiplex families from South India, " Metabolism: Clinical and Experimental, vol. 58, no. 10, pp. 1439-1445, 2009.
11. L. T. Madakamutil, I. Maricic, E. Sercarz, and V. Kumar, "Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes, " Journal of Immunology, vol. 170, no. 6, pp. 2985-2992, 2003.
12. C. Zeng, X. Shi, B. Zhang et al., "The imbalance of Th17/Th1/ Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications, " Journal of Molecular Medicine, vol. 90, no. 2, pp. 175-186, 2012.
13. M. R. Walker, D. J. Kasprowicz, V. H. Gersuk et al., "Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25? T cells, " The Journal of Clinical Investigation, vol. 112, no. 9, pp. 1437-1443, 2003.
14. H. Yi, Y. Zhen, L. Jiang, J. Zheng, and Y. Zhao, "The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells, " Cellular &Molecular Immunology, vol. 3, no. 3, pp. 189-195, 2006.
15. A. H. Banham, F. M. Powrie, and E. Suri-Payer, "FOXP3+ regulatory T cells: current controversies and future perspectives, " European Journal of Immunology, vol. 36, no. 11, pp. 2832-2836, 2006.
16. H. Yagi, T. Nomura, K. Nakamura et al., "Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells, " International Immunology, vol. 16, no. 11, pp. 1643-4656, 2004.
17. F. Mahmoud and E. Al-Ozairi, "Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes, " Disease Markers, vol. 35, no. 4, pp. 235-241, 2013.
18. E. van Exel, J. Gussekloo, A. J. M. de Craen, M. Frölich, A. B.-V. D. Wiel, and R. G. J. Westendorp, "Low production capacity of interleukin-10 associates with themetabolic syndrome and type 2 diabetes: The Leiden 85-plus study, " Diabetes, vol. 51, no. 4, pp. 1088-1092, 2002.
19. G. Kuriya, T. Uchida, S. Akazawa et al., "Double deficiency in IL-17 and IFN-γ signalling significantly suppresses the development of diabetes in the NOD mouse, " Diabetologia, vol. 56, no. 8, pp. 1773-1780, 2013.
20. K. Nakajima, T. Kanda, M. Takaishi et al., "Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model, " The Journal of Immunology, vol. 186, no. 7, pp. 4481-4489, 2011.
21. R. Derynck, A. B. Roberts, M. E. Winkler, E. Y. Chen, and D. V. Goeddel, "Human transforming growth factor-β: precursor structure and expression in E. coli, " Cell, vol. 38, no. 1, pp. 287-297, 1984.
22. W. A. Border and E. Ruoslahti, "Transforming growth factorbeta in disease: The dark side of tissue repair, " The Journal of Clinical Investigation, vol. 90, no. 1, pp. 1-7, 1992.
23. S. Yener, A. Comlekci, B. Akinci et al., "Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patientswith type 2 diabetes. Effect of metformin and rosiglitazone, " Hormones, vol. 7, no. 1, pp. 70-76, 2008.
24. K. Bouzakri and J. R. Zierath, "MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-β-induced insulin resistance, "The Journal of Biological Chemistry, vol. 282, no. 11, pp. 7783-7789, 2007.
25. P. Plomgaard, K. Bouzakri, R. Krogh-Madsen, B. Mittendorfer, J. R. Zierath, and B. K. Pedersen, "Tumor necrosis factor-β induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation, " Diabetes, vol. 54, no. 10, pp. 2939-2945, 2005.
26. J. M. Fernández-Real, C. Gutierrez, W. Ricart et al., "The TNF-α gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels, " Diabetes, vol. 46, no. 9, pp. 1468-1472, 1997.
27. R. Rosmond, M. Chagnon, C. Bouchard, and P. Björntorp, "Increased abdominal obesity, insulin and glucose levels in nondiabetic subjects with a T29C polymorphism of the transforming growth factor-β1 gene, " Hormone Research, vol. 59, no. 4, pp. 191-194, 2003.
28. K. Sharma and F. N. Ziyadeh, "Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-β as a key mediator, " Diabetes, vol. 44, no. 10, pp. 1139-1146, 1995.
29. E. Korpinen, A.-M. Teppo, L. Hukkanen, H. K. Akerblom, C. Grönhagen-Riska, and O. Vaarala, "Urinary transforming growth factor-β1 and α1-microglobulin in children and adolescents with type 1 diabetes, " Diabetes Care, vol. 23, no. 5, pp. 664-668, 2000.
30. D. Ellis, K. Y.-Z. Forrest, J. Erbey, and T. J. Orchard, "Urinary measurement of transforming growth factor-β and type IV collagen as new markers of renal injury: Application in diabetic nephropathy, " Clinical Chemistry, vol. 44, no. 5, pp. 950-956, 1998.
31. K. Sharma, F. N. Ziyadeh, B. Alzahabi et al., "Increased renal production of transforming growth factor-β1 in patients with type II diabetes, " Diabetes, vol. 46, no. 5, pp. 854-859, 1997.
32. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, " Journal of Clinical Epidemiology, vol. 62, no. 10, pp. 1006-1012, 2009.
33. G. Wells, B. Shea, D. O'Connell et al., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses, 2011, http://www. ohri. ca/programs/clinical epidemiology/oxford. Asp.
34. P. Plomgaard, A. R. Nielsen, C. P. Fischer et al., "Associations between insulin resistance and TNF-α in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes, " Diabetologia, vol. 50, no. 12, pp. 2562-2571, 2007.
35. C. M. O. Volpe, L. F. M. Abreu, P. S. Gomes, R. M. Gonzaga, C. A. Veloso, and J. A. Nogueira-Machado, "The production of nitric oxide, IL-6, and TNF-alpha in palmitate-stimulated PBMNCs is enhanced through hyperglycemia in diabetes, " Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 479587, 12 pages, 2014.
36. E. S. Yeo, J. Y. Hwang, J. E. Park, Y. J. Choi, K. B. Huh, and W. Y. Kim, "Tumor necrosis factor (TNF-α) and c-reactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes, " YonseiMedical Journal, vol. 51, no. 4, pp. 519-525, 2010.
37. S. Kado, T. Nagase, and N. Nagata, "Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus, " Acta Diabetologica, vol. 36, no. 1-2, pp. 67-72, 1999.
38. L. Lukic, N. M. Lalic, N. Rajkovic et al., "Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: potential targets for an efficient preventive intervention, " International Journal of Environmental Research and Public Health, vol. 11, no. 4, pp. 3586-3598, 2014.
39. M. Hansen, A. R. Nielsen, T. Vilsbøll et al., "Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes, " Pancreas, vol. 41, no. 8, pp. 1316-1318, 2012.
40. O. M. Andriankaja, S. P. Barros, K. Moss et al., "Levels of serum interleukin (IL)-6 and gingival crevicular fluid of IL-1β and prostaglandin E2 among non-smoking subjects with gingivitis and type 2 diabetes, " Journal of Periodontology, vol. 80, no. 2, pp. 307-316, 2009.
41. S. Guzel, A. Seven, A. Kocaoglu et al., "Osteoprotegerin, leptin and IL-6: Association with silent myocardial ischemia in type 2 diabetes mellitus, " Diabetes and Vascular Disease Research, vol. 10, no. 1, pp. 25-31, 2013.
42. Y. Aso, K. Okumura, N. Yoshida et al., "Plasma interleukin-6 is associated with coagulation in poorly controlled patients with Type 2 diabetes, " DiabeticMedicine, vol. 20, no. 11, pp. 930-934, 2003.
43. H. S. Lim, A. D. Blann, and G. Y. H. Lip, "Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention, " Circulation, vol. 109, no. 21, pp. 2524-2528, 2004.
44. P. Hui, S. Jia, W. Ma et al., "The changes and significance of IL-6 levels in patients with OSAHS associated Type 2 diabetes Mellites, " Lin Chung Er Bi Yan Hou Tou JingWaiKe Za Zhi, vol. 29, no. 19, pp. 1726-1728, 2015.
45. G. Daniele, R. Guardado Mendoza, D. Winnier et al., "The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus, " Acta Diabetologica, vol. 51, no. 1, pp. 123-131, 2014.
46. B. Gowínska and M. Urban, "Selected cytokines (Il-6, Il-8, Il-10, MCP-1, TNF-alpha) in children and adolescents with atherosclerosis risk factors: obesity, hypertension, diabetes, " Wiadomosci Lekarskie, vol. 56, no. 3-4, pp. 109-116, 2003.
47. S. T. Azar, S. C. Major, and B. Safieh-Garabedian, "Altered plasma levels of nerve growth factor and transforming growth factor-β2 in type-1 diabetes mellitus, " Brain, Behavior, and Immunity, vol. 13, no. 4, pp. 361-366, 1999.
48. S. T. Azar, I. Salti, M. S. Zantout, and S. Major, "Alterations in plasma transforming growth factor beta in normoalbuminuric type 1 and type 2 diabetic patients, " Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4680-4682, 2000.
49. D. Jun-Wen, W. Tao, and N. Guo-Zhen, "The level about the TGF-β1 and proto-oncogene proteins c-sis in peripheral blood of T2DM patients with nephropathy and the clinical applications, " Clinical Focus, vol. 22, no. 11, pp. 793-794, 2007 (Chinese).
50. D. Z. Chi, "Association of serum transforming growth factor-(TGF-β1), type IV collagen and laminin with diabetic nephropathy in type 2 diabetic patients, " Heilongjiang Medicine Journal, vol. 26, no. 3, pp. 402-407, 2013 (Chinese).
51. S. Ehnert, T. Freude, C. Ihle et al., "Factors circulating in the blood of type 2 diabetes mellitus patients affect osteoblast maturation-description of a novel in vitromodel, " Experimental Cell Research, vol. 332, no. 2, pp. 247-258, 2015.
52. F. Changxin, "Clinical significance of determination of serum cystatin C, transforming growth factor beta1(TGF-β1) and urine microalbumin levels in patients with DM2 nephropathy, " Journal of Radioimmunology, vol. 20, no. 5, pp. 471-474, 2007 (Chinese).
53. B. Hellmich, M. Schellner, H. Schatz, and A. Pfeiffer, "Activation of transforming growth factor-β1 in diabetic kidney disease, " Metabolism, vol. 49, no. 3, pp. 353-359, 2000.
54. C. Herder, A. Zierer, W. Koenig, M. Roden, C. Meisinger, and B. Thorand, "Transforming growth factor-β1 and incident type 2 diabetes: results from theMONICA/KORAcase-cohort study, 1984-2002, " Diabetes Care, vol. 32, no. 10, pp. 1921-1923, 2009.
55. J. Hai-bing, G. Pei-zhen, and L. Jing, "Changes in serumTGF-β1 in type 2 diabetic patients, " Chinese Journal of Pathophysiology, vol. 17, no. 11, pp. 1085-1087, 2001 (Chinese).
56. L. Zhen-zuo, L. Lin, and X. Rui-yan, "Clinical study of serum matrix metalloproteinase-9 and transforming growth factor-β1 related with type 2 diabetic patients with nephropathy, " Journal of Taishan Medical College, vol. 26, no. 6, pp. 530-534, 2005 (Chinese).
57. L. Rui-Ji and L. Lan-Ji, "The level about theHGF and TGF-β1 in peripheral blood of T2DM patients with nephropathy and the clinical applications, " Hebei Medical Journal, vol. 33, no. 12, pp. 1806-1808, 2011 (Chinese).
58. L. Da-wei, Z. Zhi, and L. Kun, "Serum transforming growth factor-β levels in patients with diabetic retinopathy, " Journal of Shanghai Jiaotong University (Medical Science), vol. 33, no. 7, pp. 990-993, 2013 (Chinese).
59. A. Pfeiffer, K. Middelberg-Bisping, C. Drewes, and H. Schatz, "Elevated plasma levels of transforming growth factor-β1 in NIDDM, " Diabetes Care, vol. 19, no. 10, pp. 1113-1117, 1996.
60. W. Yan-Jun, H. Ping, and L. Li-Ping, "Determination and clinical significance analysis of IL-6, TNF-α and TGF-β1 in the patients with diabetic nephropathy, " Chinese Journal of Scientific and Technical Periodicals, vol. 18, no. 3, pp. 214-215, 2002.
61. W. Yaping, "Clinical significance of deterermination of changes of plasma ET and serum TGF-β1, VEGF levels in patients with 2-type diabetes, " Journal of Neuroimmunology, vol. 21, no. 6, pp. 529-532, 2008 (Chinese).
62. W. Ye-Sheng, L. Yan, and Y. Yan-Wu, "The serum level and the genotype of TGF-β1 in patients with type 2 diabetic nephropathy, " Chinese Journal of Laboratory Medicine, vol. 128, no. 2, pp. 173-178, 2005.
63. W. Ming-bin, L. Jing-dong, and H. Ya-nan, "The abnormal and clinical applications about TGF-β1 in diabetes mellitus, " Practical Clinical Medicine, vol. 3, no. 6, pp. 82-83, 2002 (Chinese).
64. J. Chun-Yan, Y. Shan-Dong, and C. Yan, "The change of serumand urinary transforming growth factor-beta-1 and their clinical significances in type 2 diabetics, " Chinese Journal of Laboratory Diagnosis, vol. 9, no. 2, pp. 286-289, 2005 (Chinese).
65. N. Yuan, The Expression of CD4+CD25+Foxp3+Treg and the Level of Related Cytokine(IL-10, TGF-β) in the Newly Diagnosed Type 2 Diabetic Patients, Jilin University, 2011.
66. Z. Wei-jie and L. Kai, "Association between changes in transforming growth factor-β1 level and type 2 diabetic nephropathy, " Journal of Clinical Rehabilitative Tissue Engineering Research, vol. 11, no. 49, pp. 9838-9842, 2007 (Chinese).
67. Y. Zhou, X. Su, and S. Ke, "Relationship between serum levels of transforming growth factor-β1, tumor necrosis factor-β and diabetic nephropathy, " Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, vol. 34, no. 4, pp. 441-444, 2005 (Chinese).
68. S. Yaturu, J. Rains, and S. K. Jain, "Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-α levels in men with type 2 diabetes, " Cytokine, vol. 44, no. 1, pp. 168-171, 2008.
69. X. Lin, Z. Zhang, J. M. Chen et al., "Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease, " Genetics and Molecular Research, vol. 14, no. 2, pp. 2940-2946, 2015.
70. F. Haseda, A. Imagawa, Y. Murase-Mishiba, J. Terasaki, and T. Hanafusa, "CD4+CD45RaFoxP3high activated regulatory T cells are functionally impaired and related to residual insulinsecreting capacity in patients with type 1 diabetes, " Clinical and Experimental Immunology, vol. 173, no. 2, pp. 207-216, 2013.
71. R. Li, The Expression of CD4+CD25+Foxp3+Treg in the Newly Diagnosed Type 2 Diabetic Patients, Jilin University, 2011.
72. W. Li, G. Hong, and W. Xi, "The expression of Treg andThcells in peripheral blood of old T2DM patients with nephropathy in different stages, " Chinese Journal of Gerontology, no. 18, pp. 9-10, 2014 (Chinese).
73. X. Jing, S. Hong-Li, and W. Jun-Hong, "Role of CD4+CD25+FOXP3+ regulatory T cells in type 2 diabetic nephropathy, " Journal of Southern Medical University, vol. 29, no. 1, pp. 137-140, 2009 (Chinese).
74. S. Zhang, TheClinical and Laboratory Study ofDifferentialDiagnosis of Young and Middle-Aged Non-Obses Diabetes Patients, Peking Union Medical College Hospital, Beijing, China, 2009 (Chinese).
75. X.-J. Zhang, L.-L. Kong, and R. Gu, "Percentages of FOXP3+ regulatory T cells in patients with diabetes, " Acta Universitatis Medicinalis Nanjing (Natural Science), vol. 32, no. 4, pp. 509-514, 2012 (Chinese).
76. A. B. Acharya, S. Thakur, and M. V. Muddapur, "Effect of scaling and root planing on serum interleukin-10 levels and glycemic control in chronic periodontitis and type 2 diabetes mellitus, " Journal of Indian Society of Periodontology, vol. 19, no. 2, pp. 188-193, 2015.
77. M. Dworacka, S. Iskakova, E. Krzyzagorska et al., "Alpha-lipoic acid modifies circulating angiogenic factors in patients with type 2 diabetesmellitus, "Diabetes Research andClinical Practice, vol. 107, no. 2, pp. 273-279, 2015.
78. F. You-fei, W. Jing, and Y. Song, "Expressions of IL-10 and TGF-β and their relations with islet beta cell function in adults with latent autoimmune diabetes, " Journal of Shangdong University, vol. 47, no. 10, pp. 15-19, 2009 (Chinese).
79. K. Ling-Xia, Study on the Serum IL-10, IL-18 Levels in Patients with Chronic Obstructive Pulmonary Disease with Type 2 Diabetes, Jilin University, Changchun, China, 2013 (Chinese).
80. Y.-L. Li, Th1/Th2/Th17/Treg Cytokines Expression Levels in the Periphral Blood of Type 2 Diabetes Patients, Southern Medical University, 2014 (Chinese).
81. L. Chen, Z. Ying, and H. Ying, "The clinical applications of the detection about the level of IL-6, IL-10 in T2DM patients with early phase nephropathy, " Modern Diagnosis & Treatment, vol. 25, no. 14, pp. 3319-3320, 2014 (Chinese).
82. S. Hong, L. Chao, and B. Ruifang, "Study on the relationships between T lymphocyte subgroup, serous TNF-α and IL-10 in type 2 diabetic mellitus patients, " Tianjin Medical Journal, vol. 35, no. 11, pp. 823-826, 2007 (Chinese).
83. A. Al-Shukaili, S. Al-Ghafri, S. Al-Marhoobi, S. Al-Abri, J. Al-Lawati, and M. Al-Maskari, "Analysis of inflammatory mediators in type 2 diabetes patients, " International Journal of Endocrinology, vol. 2013, Article ID 976810, 7 pages, 2013.
84. W. Xiaojing, "The relativity study of serumIL-18, IL-10 in type 2 Diabetes patients, " Medical Laboratory Science and Clinics, vol. 19, no. 2, pp. 53-55, 2008 (Chinese).
85. W. Yue-Ying, C. Li-Juan, and Q. Hui, "Relationship between plasma IL-10 level and T2DM macrovascular complications, " Chinese General Practice, vol. 13, no. 1, pp. 235-236, 2010 (Chinese).
86. X. Wei, Z. Hang, and S.-J. Wang, "Thecorrelation about IL-8, IL-10 and IL-18 with T2DM patients with ephropathy in different stages, " The Journal of Practical Medicine, vol. 29, no. 13, pp. 2158-2161, 2013 (Chinese).
87. X. Jing, Z. Xiang, and S. Sheng-gang, "Clinical significance of combined detection of serum IL-8 and IL-10 levels for diagnosis of type 2 diabetic nephropathy, " Medical Innovation of China, vol. 10, no. 12, pp. 121-122, 2013 (Chinese).
88. N. Yaghini, M. Mahmoodi, G. R. Asadikaram, G. H. Hassanshahi, H. Khoramdelazad, and M. Kazemi Arababadi, "Serum levels of interleukin 10 (IL-10) in patients with type 2 diabetes, " Iranian Red CrescentMedical Journal, vol. 13, no. 10, p. 752, 2011.
89. Z. Hua, L.-X. Liu, and L. Zhi, "The changes and significance about IL-6, IL-10 and TNF-α level in peripheral blood of DM patients with hypertension, " Shandong Medical Journal, vol. 55, no. 19, pp. 79-80, 2015 (Chinese).
90. Z. Zhao-Hui, J. Xiao-Jun, and B. Su-Yu, "The level of IL-10 and IL-18 in peripheral blood of T2DM with chronic obstructive pulmonary diseases and the correlational research about lung function, " Journal of Community Medicine, vol. 12, no. 20, pp. 19-20, 2014 (Chinese).
91. N. Afzal, K. Javaid, S. Zaman, A. Zafar, and A. H. Nagi, "Enumeration of CD4+CD25+T regulatory cells in Type-II diabetes retinopathy, " Pakistan Journal of Pharmaceutical Sciences, vol. 27, no. 5, pp. 1191-1197, 2014.
92. L. Chi, H.-M. Wu, and X.-F. Xu, "The detection about the subgroup of regulatory cells in peripheral blood of T2DM patients and its clinical applications, " ShandongMedical Journal, vol. 51, no. 40, pp. 87-90, 2011 (Chinese).
93. H. Ling, Z. Zhiguang, and L. Jianhua, "Changes of CD4+CD25+ T cell subsets in LADA patients, " Chinese Journal of Diabetes, vol. 13, no. 6, pp. 428-431, 2006 (Chinese).
94. A. Kukreja, G. Cost, J. Marker et al., "Multiple immunoregulatory defects in type-1 diabetes, " The Journal of Clinical Investigation, vol. 109, no. 1, pp. 131-140, 2002.
95. L. Hong, L. Jia-Xuan, and Z. Zhi-Zhe, "Changes of CD4+CD25+ regulatory T cells in peripheral blood of diabetes mellitus complicated with pulmonary infection and its significance, " Guangxi Medical Journal, vol. 33, no. 2, pp. 162-164, 2011 (Chinese).
96. H. Li, Z.-Z. Zhang, and S.-P. Li, "The changes and significances of CD4+CD25+ regulatory T cells in peripheral blood of diabetes patients with angiopathy, " Internal Medicine of China, vol. 7, no. 2, pp. 104-107, 2012 (Chinese).
97. T. Ye-Hai, D. Yu-Yun, and C. Jiang-Nan, "The dection of CD4+CD25+ regulatory cells in peripheral blood of diabetes mellitus patients with pulmonary tuberculosis, " Chinese Journal of Health Laboratory Technology, vol. 21, no. 11, pp. 2703-2704, 2011 (Chinese).
98. W.-Y. Wu, L.-S. Tang, and F. Li, "Changes and significance of CD4+CD25+T cells and expression of FOXP3 mRNA in peripheral blood mononuclear cell from patients with PDR, " International Eye Science, vol. 15, no. 3, pp. 398-504, 2015 (Chinese).
99. Z. Yang, Z. Zhou, G. Huang et al., "The CD4+ regulatory Tcells is decreased in adults with latent autoimmune diabetes, " Diabetes Research and Clinical Practice, vol. 76, no. 1, pp. 126-131, 2007.
100. X. Yang, "The quantity about CD4+CD25+ regulatory cells in peripheral blood of T1DMpatients and its influencewith insulin therapy, " Shandong Medical Journal, vol. 54, no. 10, pp. 78-79, 2014 (Chinese).
101. Y. Xue-he, Q. Jin-yao, and L. Shen, "Study on the level of CD4+CD25+ and CD8+CD28? regulatory T cell in the peripheral blood of patients with type 1 diabetes mellitus, " Chinese Journal of Diabetes Mellitus, vol. 17, no. 6, pp. 473-476, 2009 (Chinese).
102. Q. Zhang, H. Xiao, and B. Su, "Clinical significance of CD4+CD25high T cells in patients with pulmonary tuberculosis complicatedby type2diabetesmellitus, "TheChineseMedical Association of TB Academic, pp. 195-199, 2010 (Chinese).
103. Z. Tao, Z. Shirong, and Z. Jing, "Relationships of latent autoimmune diabetes in adults with regulatory T cells and Foxp3 expression, " Immunological Journal, vol. 27, no. 12, pp. 1063-1067, 2011 (Chinese).
104. R. Zhang and S. Bi-Wen, "Changes and significance of CD4+CD28+T cells, CD4+CD25+T cells in type 2 diabetes and its macrovascular complications, " Clinical Journal of Chinese Medicine, vol. 5, no. 18, pp. 110-111, 2013 (Chinese).
105. C. D. C. Pernet Hara, E. L. França, D. L. Gomes et al., "Characterization of natural killer cells and cytokines in maternal placenta and fetus of diabetic mothers, " Journal of Immunology Research, vol. 2016, Article ID 7154524, 8 pages, 2016.
106. Y. Suzuki, M. Nakazawa, K. Suzuki, H. Yamazaki, and Y. Miyagawa, "Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion, " Japanese Journal of Ophthalmology, vol. 55, no. 3, pp. 256-263, 2011.
107. N. Afzal, S. Zaman, A. Asghar et al., "Negative association of serumIL-6 and IL-17 with type-II diabetes retinopathy, " Iranian Journal of Immunology, vol. 11, no. 1, pp. 40-48, 2014.
108. M. K. Arababadi, R. Nosratabadi, G. Hassanshahi et al., "Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases?" Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 33-37, 2010.
109. S. Liu, Y. U. Lin, and X. Liu, "Protective effects of SIRT1 in patients with proliferative diabetic retinopathy via the inhibition of IL-17 expression, " Experimental and Therapeutic Medicine, vol. 11, no. 1, pp. 257-262, 2016.
110. A. Roohi, M. Tabrizi, F. Abbasi et al., "Serum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and agematched healthy controls, " BioMed Research International, vol. 2014, Article ID718946, 7 pages, 2014.
111. Y. Zhan and L. Jiang, "Status of vitaminD, antimicrobial peptide cathelicidin and T helper-associated cytokines in patients with diabetes mellitus and pulmonary tuberculosis, " Experimental andTherapeutic Medicine, vol. 9, no. 1, pp. 11-16, 2015.
112. I. V. Kologrivova, T. E. Suslova, O. A. Koshel'Skaya, I. V. Vinnitskaya, and O. A. Trubacheva, "System of matrix metalloproteinases and cytokine secretion in type 2 diabetes mellitus and impaired carbohydrate tolerance associated with arterial hypertension, " Bulletin of Experimental Biology and Medicine, vol. 156, no. 5, pp. 635-638, 2014.
113. B. Bilir, F. Tulubas, B. E. Bilir et al., "The association of vitamin D with inflammatory cytokines in diabetic peripheral neuropathy, " Journal of Physical Therapy Science, vol. 28, no. 7, pp. 2159-2163, 2016.
114. R. Vasanthakumar, V. Mohan, G. Anand, M. Deepa, S. Babu, and V. Aravindhan, "Serum IL-9, IL-17, and TGF-β levels in subjects with diabetic kidney disease (CURES-134), " Cytokine, vol. 72, no. 1, pp. 109-112, 2015.
115. S. Hori, T. Nomura, and S. Sakaguchi, "Control of regulatory T cell development by the transcription factor Foxp3, " Science, vol. 299, no. 5609, pp. 1057-1061, 2003.
116. T. T. Yang, S. J. Song, H. B. Xue, D. F. Shi, C. M. Liu, and H. Liu, "Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155, " European Review for Medical and Pharmacological Sciences, vol. 19, no. 11, pp. 2010-2015, 2015.
117. S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, "Regulatory T cells and immune tolerance, " Cell, vol. 133, no. 5, pp. 775-787, 2008.
118. F. X.-F. Qin, "Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host, " Cellular & Molecular Immunology, vol. 6, no. 1, pp. 3-13, 2009.
119. J. Huehn, J. K. Polansky, and A. Hamann, "Epigenetic control of FOXP3 expression: The key to a stable regulatory T-cell lineage" Nature Reviews Immunology, vol. 9, no. 2, pp. 83-89, 2009.
120. S. G. Zheng, J. H. Wang, J. D. Gray et al., "Natural and induced CD4+CD25+ cells educate CD4+CD25? cells to develop suppressive activity: The role of IL-2, TGF-β, and IL-10, "The Journal of Immunology, vol. 172, no. 9, pp. 5213-5221, 2004.
121. D. F. Fiorentino, M. W. Bond, and T. R. Mosmann, "Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production byTh1 clones, "The Journal of Experimental Medicine, vol. 170, no. 6, pp. 2081-2095, 1989.
122. J. C. Marie, J. J. Letterio, M. Gavin, and A. Y. Rudensky, "TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells, " The Journal of Experimental Medicine, vol. 201, no. 7, pp. 1061-1067, 2005.
123. E. M. Shevach, T. S. Davidson, E. N. Huter, R. A. DiPaolo, and J. Andersson, "Role of TGF-β in the induction of Foxp3 expression and T regulatory cell function, " Journal of Clinical Immunology, vol. 28, no. 6, pp. 640-646, 2008.
124. H. Wu, Y. Nie, H. Xiong et al., "P2X7 receptor expression in peripheral blood monocytes is correlated with plasma Creactive protein and cytokine levels in patients with type 2 diabetes mellitus: A preliminary report, " Inflammation, vol. 38, no. 6, pp. 2076-2081, 2015.
125. M. A. Febbraio and B. K. Pedersen, "Muscle-derived interleukin-6: mechanisms for activation and possible biological roles, " The FASEB Journal, vol. 16, no. 11, pp. 1335-1347, 2002.
126. V. Mohamed-Ali, S. Goodrick, A. Rawesh et al., "Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-β, in vivo, " Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 12, pp. 4196-4200, 1997.
127. R. L. Starkie, M. J. Arkinstall, I. Koukoulas, J. A. Hawley, and M. A. Febbraio, "Carbohydrate ingestion attenuates the increase in plasma interleukin-6, but not skeletal muscle interleukin-6 mRNA, during exercise in humans, " The Journal of Physiology, vol. 533, no. 2, pp. 585-591, 2001.
128. B. K. Pedersen, A. Steensberg, and P. Schjerling, "Musclederived interleukin-6: possible biological effects, " Journal of Physiology, vol. 536, no. 2, pp. 329-337, 2001.
129. M. Fujimoto, M. Nakano, F. Terabe et al., "The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells, " Journal of Immunology, vol. 186, no. 1, pp. 32-40, 2011.
130. E. Bettelli, M. Oukka, and V. K. Kuchroo, "TH-17 cells in the circle of immunity and autoimmunity, "Nature Immunology, vol. 8, no. 4, pp. 345-350, 2007.
131. M. Jagannathan-Bogdan, M. E. McDonnell, H. Shin et al., "Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes, " Journal of Immunology, vol. 186, no. 2, pp. 1162-1172, 2011.
132. P. Dandona, A. Aljada, and A. Bandyopadhyay, "Inflammation: The link between insulin resistance, obesity and diabetes, " Trends in Immunology, vol. 25, no. 1, pp. 4-7, 2004.
133. J. C. Pickup, "Inflammation and activated innate immunity in the pathogenesis of type 2 diabletes, " Diabetes Care, vol. 27, no. 3, pp. 813-823, 2004.
134. H. Guan, P. S. Nagarkatti, and M. Nagarkatti, "CD44 reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis, " The Journal of Immunology, vol. 186, no. 12, pp. 6955-6964, 2011.
135. G. L. King, "The role of inflammatory cytokines in diabetes and its complications, " Journal of Periodontology, vol. 79, no. 8, pp. 1527-1534, 2008.
136. S. E. Shoelson, L. Herrero, and A. Naaz, "Obesity, inflammation, and insulin resistance, " Gastroenterology, vol. 132, no. 6, pp. 2169-2180, 2007.
137. S. W. Ha, H. J. Kim, J. S. Bae et al., "Elevation of urinary βigh3, transforming growth factor-β-induced protein in patients with type 2 diabetes and nephropathy, " Diabetes Research and Clinical Practice, vol. 65, no. 2, pp. 167-173, 2004.
138. T. Mandrup-Poulsen, "IAPP boosts islet macrophage IL-1 in type 2 diabetes, " Nature Immunology, vol. 11, no. 10, pp. 881-883, 2010.
139. C. M. Larsen, M. Faulenbach, A. Vaag et al., "Interleukin-1-receptor antagonist in type 2 diabetes mellitus, " The New England Journal ofMedicine, vol. 356, no. 15, pp. 1517-1526, 2007